Key result
Everolimus-eluting BRS yield ~22% TLF at five years without late scaffold thrombosis.
Observational (n=176)
No
In a real-world registry, everolimus-eluting bioresorbable scaffolds showed high rates of clinical events at 5 years, though no scaffold thrombosis occurred after 2 years.
Long-term BRS outcomes in all-comers remain uncertain; extends sparse registry data but leaves open routine use pending randomized trials.
OBJECTIVES: The aim of this study was to evaluate very long-term results after unrestricted everolimus-eluting bioresorbable scaffolds (BRS) implantation. BACKGROUND: Previous randomized studies mainly included selected patients differing from those seen during daily routine and long-term data from all-comers registries are sparse. METHODS: Consecutive patients undergoing BRS implantation were included in this observational, single center study. Clinical follow-up was conducted up to 5 years. Endpoint of interest was the composite of target lesion failure (TLF), including target-vessel myocardial infarction and target lesion revascularization and cardiac death. Furthermore, ARC-defined scaffold thrombosis (ScT) were assessed. RESULTS: A total of 176 patients with a median age of 64 (55 - 72) years were analyzed, of which 59.6% presented an acute coronary syndrome. A total of 183 mainly complex lesions (55.8%) were treated. At 5 years, the rate for TLF was 21.6%. Definite or probable ScT rate was 4.1%. The rate of ScT within the first year was 2.8% and afterwards 1.2%. Notably, no ScT was seen later than 2 years. CONCLUSIONS: Although this real-world registry displays high rates of clinical events during long-term follow-up, no ScT was seen after 2 years.
No takes yet. Share an insight, caveat, or question.
Wiebe et al. (2020) conducted an observational in Acute coronary syndrome and complex coronary lesions (n=176). Everolimus-eluting bioresorbable scaffolds (BRS) implantation was evaluated on Composite of target lesion failure (TLF), including target-vessel myocardial infarction and target lesion revascularization and cardiac death. Everolimus-eluting bioresorbable scaffold implantation resulted in a 21.6% rate of target lesion failure at 5 years, with no scaffold thrombosis observed after 2 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: